Home › Trial NCT03362606
Engineered Immune Effectors Against Ovarian Cancer
- Trial IDNCT03362606
- StatusTerminated
- PhasePhase 1/2
- Study typeInterventional
- SponsorShenzhen Geno-Immune Medical Institute
- Enrollment20
- Start date2026-06-01
- ConditionsOvarian Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.